文献速递肺血管病与心包/心肌炎

Regnase-1通过降解肺泡巨噬细胞IL-6与PDGF mRNA预防肺动脉高压

Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.
PubMed 文献 · Circulation · 2022-08-23

该研究探讨Regnase-1在肺动脉高压(PAH)中的作用。患者外周血单核细胞中ZC3H12A表达与PH预后和严重程度负相关,尤其在结缔组织病相关PAH中。肺泡巨噬细胞缺失Regnase-1的小鼠自发严重PAH,转录组分析提示Il6、Il1b、Pdgfa/b为靶点,抑制IL-6或PDGF可改善PAH。

要点

  • PH患者PBMC中ZC3H12A表达与预后和疾病严重程度负相关。
  • 肺泡巨噬细胞缺失Regnase-1的小鼠自发严重PAH。
  • 抑制IL-6或PDGF可改善小鼠PAH,抑制IL-1β无效。

核心结论

  • Regnase-1通过控制肺泡巨噬细胞中IL-6和PDGF维持肺先天免疫稳态,从而抑制小鼠PAH发生。
  • PH患者中Regnase-1表达降低提示其参与PH发病,可能作为疾病生物标志物和治疗靶点。

研究设计与样本

  • 先检测不同类型PH患者外周血单核细胞中ZC3H12A表达并与临床特征关联。
  • 构建髓系细胞(含肺泡巨噬细胞)特异性缺失Regnase-1的小鼠,检测右心室收缩压和肺组织学改变。
  • 对小鼠肺泡巨噬细胞和肺动脉进行转录组分析,识别Regnase-1调控的基因。

主要发现

  • PH患者PBMC中ZC3H12A表达与预后和疾病严重程度呈负相关,尤其在结缔组织病相关PAH中。
  • 肺泡巨噬细胞缺失Regnase-1的小鼠自发严重PAH,表现为右心室收缩压升高和不可逆肺血管重塑。
  • 转录组分析显示Il6、Il1b和Pdgfa/b是肺泡巨噬细胞中Regnase-1调控PAH的潜在靶点。
  • 抗IL-6受体抗体抑制IL-6或伊马替尼抑制PDGF可改善PAH,而阿那白滞素抑制IL-1β无效。

临床怎么用

  • Regnase-1表达水平可能作为PH(尤其结缔组织病相关PAH)的预后和严重程度生物标志物。
  • 靶向IL-6或PDGF通路可能为PAH治疗策略,但需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension (PH) characterized by obliterative pulmonary vascular remodeling, resulting in right-sided heart failure. Although the pathogenesis of PAH is not fully understood, inflammatory responses and cytokines have been shown to be associated with PAH, in particular, with connective tissue disease-PAH. In this sense, Regnase-1, an RNase that regulates mRNAs encoding genes related to immune reactions, was investigated in relation to the pathogenesis of PH. METHODS: We first examined the expression levels of ZC3H12A (encoding Regnase-1) in peripheral blood mononuclear cells from patients with PH classified under various types of PH, searching for an association between the ZC3H12A expression and clinical features. We then generated mice lacking Regnase-1 in myeloid cells, including alveolar macrophages, and examined right ventricular systolic pressures and histological changes in the lung. We further performed a comprehensive analysis of the transcriptome of alveolar macrophages and pulmonary arteries to identify genes regulated by Regnase-1 in alveolar macrophages. RESULTS: ZC3H12A expression in peripheral blood mononuclear cells was inversely correlated with the prognosis and severity of disease in patients with PH, in particular, in connective tissue disease-PAH. The critical role of Regnase-1 in controlling PAH was also reinforced by the analysis of mice lacking Regnase-1 in alveolar macrophages. These mice spontaneously developed severe PAH, characterized by the elevated right ventricular systolic pressures and irreversible pulmonary vascular remodeling, which recapitulated the pathology of patients with PAH. Transcriptomic analysis of alveolar macrophages and pulmonary arteries of these PAH mice revealed that Il6, Il1b, and Pdgfa/b are potential targets of Regnase-1 in alveolar macrophages in the regulation of PAH. The inhibition of IL-6 (interleukin-6) by an anti-IL-6 receptor antibody or platelet-derived growth factor by imatinib but not IL-1β (interleukin-1β) by anakinra, ameliorated the pathogenesis of PAH. CONCLUSIONS: Regnase-1 maintains lung innate immune homeostasis through the control of IL-6 and platelet-derived growth factor in alveolar macrophages, thereby suppressing the development of PAH in mice. Furthermore, the decreased expression of Regnase-1 in various types of PH implies its involvement in PH pathogenesis and may serve as a disease biomarker, and a therapeutic target for PH as well.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Yaku A, Inagaki T, Asano R, et al. Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages. Circulation. 2022. PMID: 35997026. doi:10.1161/CIRCULATIONAHA.122.059435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。